- Home
- CHRS vs SCPH Comparison
CHRS vs SCPH Comparison
Compare CHRS & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SCPH
- Stock Information
- Founded
- CHRS 2010
- SCPH 2013
- Country
- CHRS United States
- SCPH United States
- Employees
- CHRS N/A
- SCPH N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- SCPH Health Care
- Exchange
- CHRS Nasdaq
- SCPH Nasdaq
- Market Cap
- CHRS 191.3M
- SCPH 160.6M
- IPO Year
- CHRS 2014
- SCPH 2017
- Fundamental
- Price
- CHRS $1.24
- SCPH $3.29
- Analyst Decision
- CHRS Strong Buy
- SCPH Strong Buy
- Analyst Count
- CHRS 4
- SCPH 2
- Target Price
- CHRS $5.38
- SCPH $15.00
- AVG Volume (30 Days)
- CHRS 2.0M
- SCPH 280.7K
- Earning Date
- CHRS 03-12-2025
- SCPH 03-12-2025
- Dividend Yield
- CHRS N/A
- SCPH N/A
- EPS Growth
- CHRS N/A
- SCPH N/A
- EPS
- CHRS N/A
- SCPH N/A
- Revenue
- CHRS $304,340,000.00
- SCPH $30,278,000.00
- Revenue This Year
- CHRS $2.47
- SCPH $172.64
- Revenue Next Year
- CHRS N/A
- SCPH $131.43
- P/E Ratio
- CHRS N/A
- SCPH N/A
- Revenue Growth
- CHRS 44.19
- SCPH 303.87
- 52 Week Low
- CHRS $0.66
- SCPH $3.08
- 52 Week High
- CHRS $2.87
- SCPH $6.54
- Technical
- Relative Strength Index (RSI)
- CHRS 37.51
- SCPH 42.86
- Support Level
- CHRS $1.38
- SCPH $3.13
- Resistance Level
- CHRS $1.45
- SCPH $3.59
- Average True Range (ATR)
- CHRS 0.13
- SCPH 0.20
- MACD
- CHRS -0.04
- SCPH -0.02
- Stochastic Oscillator
- CHRS 4.50
- SCPH 24.19
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.